Back to news

Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology

Globe Newswire•16/11/2026•06:00 ET
0

Key Highlights

  • ➤21,612 patients enrolled across 35 U.S. states in largest prospective WCD study
  • ➤ASSURE converted all 303 analyzable VT/VF shock events successfully
  • ➤Inappropriate-shock rate 0.0065 per patient-month beat prespecified safety goal
  • ➤Patients wore ASSURE 23.1 hours daily; 30% continued beyond 90 days
  • ➤VT/VF risk persisted beyond first month, with 2.6% experiencing events

Expert Statements

Jeanne E. Poole, Professor of Medicine at the University of Washington and Principal Investigator

“Advances in medical therapy have improved cardiac recovery after a myocardial infarction or a new heart failure diagnosis, but the recovery period can leave patients vulnerable to life-threatening ventricular arrhythmias.”

Jeanne E. Poole, Professor of Medicine at the University of Washington and Principal Investigator

“ACE-PAS confirmed the early risk of ventricular tachycardia and ventricular fibrillation (VT/VF) and demonstrates why WCD protection matters: it provides an opportunity to prevent sudden cardiac death while giving patients time to recover.”

Brian Webster, President and CEO of Kestra Medical Technologies

“Publication of the ACE-PAS results marks an important milestone in advancing the evidence base for wearable defibrillator therapy and monitoring.”

Brian Webster, President and CEO of Kestra Medical Technologies

“Real-world evidence at this scale reinforces confidence in the ASSURE system and strengthens the clinical foundation for protecting patients during recovery.”

Brian Webster, President and CEO of Kestra Medical Technologies

“We will continue to build on these insights to give providers more ways to protect at risk patients.”

KIRKLAND, Wash., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced publication of primary results from the ASSURE(®) WCD Clinical Evaluation Post-Approval Study (ACE-PAS) in the Journal of Cardiovascular Electrophysiology. The largest prospective real-world study of wearable cardioverter defibrillators (WCD) to date, ACE-PAS enrolled 21,612 patients across 35 U.S. states and met both primary safety and effectiveness endpoints. The study demonstrated 100% all-shock conversion success and sustained daily wear, while documenting ventricular arrhythmias early and continuously over subsequent months. The findings strengthen the clinical case for the ASSURE system across WCD indications and underscore the importance of protecting patients throughout periods of elevated arrhythmic risk.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in